Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2068)	1/2/2008 1:42:47 PM
From: Jibacoa	Respond to of 3722

NVD has been up 40%, but is up only 33% at present <g> The volume is above its ADV, but still not quite the 2M traded on Monday <g> bigcharts.marketwatch.com NVD is developing oral spray formulations for a broad range of drugs. The oral sprays have the potential for faster absorption,& onset of therapeutic effects & possibly reduced first pass liver metabolism, which could result in effective lower doses, besides the fact that eliminate the requirement for water or the need to swallow. Its most advanced drug is zolpidem oral spray, generic for Ambien, for insomnia & sumatriptan oral spray, for the treatment of migraine headaches, which may be particularly useful for patients whose nausea and vomiting preclude them from using oral migraine medication or for patients who prefer not to use an injectable migraine medication. As of Sep 30 NVD reportedly had around $13.5M in total assets & $5.85M in total liabilities. Will see if the January Effect will help NVD to get back at the $1 level.<g> bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (2068)	10/14/2008 10:45:33 AM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

NEOL opened wth an UG & is up 26% on light volume. <g> bigcharts.marketwatch.com There are no recent news that I am aware. The stock trades around 0.25xBV, it has small LTD, insiders hold around 20% & did some buying in May & early Jun. It has trimmed some its losses in the first 2Qs. Resistance is at the $0.25 level and more important at the $0.30 & $0,40 level before it can test the trendline coming from its June H at the $0.88 level.<g> bigcharts.marketwatch.com Bernard